How Much Amyloid Clearance, How Fast Is Needed To Slow Alzheimer’s?

Questions Remain But CTAD Data Offer Clues

 
• By Mandy Jackson

Lilly’s donanemab showed faster, deeper amyloid clearance versus Biogen/Eisai’s Aduhelm and Roche’s failed Phase III gantenerumab studies showed the importance of deep, rapid removal.

Amyloid plaques forming between neurons
How soon and how much amyloid clearance is needed to provide benefit may be the field's next big area of debate • Source: Shutterstock

More from Clinical Trials

More from R&D